Market Cap 11.02B
Revenue (ttm) 705.14M
Net Income (ttm) -453.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -64.37%
Debt to Equity Ratio 0.09
Volume 2,579,700
Avg Vol 2,643,876
Day's Range N/A - N/A
Shares Out 159.39M
Stochastic %K 99%
Beta 0.33
Analysts Strong Sell
Price Target $71.69

Company Profile

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treat...

Industry: Biotechnology
Sector: Healthcare
Phone: 760 931 9200
Address:
2855 Gazelle Court, Carlsbad, United States
MoneyGroupLLC
MoneyGroupLLC Oct. 4 at 1:10 AM
Enter: $IONS NOV 21 2025 $68 CALLS Buy in Price: $3.95 - $5.60 Take Profit: $7.43 Stop Bleeding: $3.48 ROI Potential: 88% Exit Within: 174 Minutes https://moneygroup.us/alerts
0 · Reply
johnnygogogo
johnnygogogo Oct. 3 at 4:57 PM
$IONS IYAWNIS cc @skeezbag
1 · Reply
SweepCastApp
SweepCastApp Oct. 3 at 3:13 PM
$IONS: Unusual Options Activity Alerted CALL flow observed 300x contracts at Strike price of $70 Exp on 11/21/2025 with Premium of $87K and showing BULLISH Sentiment
0 · Reply
SweepCastApp
SweepCastApp Sep. 30 at 8:12 PM
$IONS: Unusual Options Activity Alerted CALL flow observed 43x contracts at Strike price of $65 Exp on 01/16/2026 with Premium of $27K and showing BEARISH Sentiment
0 · Reply
highnihilism
highnihilism Sep. 30 at 7:34 AM
$LU Lufax: 407 trades, $406K vs $24K avg (17.2x). $383K calls / $23K puts. 99% single-leg. $MTZ Mastec: 224 trades, $462K vs $819K avg (0.56x). $381K calls / $81K puts. 91% single-leg. $LASR Nlight: 82 trades, $384K vs $81K avg (4.75x). $380K calls / $4K puts. 100% single-leg. $IONS Ionis Pharmaceuticals: 123 trades, $438K vs $568K avg (0.77x). $379K calls / $60K puts. 91% single-leg.
0 · Reply
JarvisFlow
JarvisFlow Sep. 26 at 4:59 PM
Goldman Sachs has updated their rating for Ionis Pharmaceuticals ( $IONS ) to Neutral with a price target of 65.
1 · Reply
SweepCastApp
SweepCastApp Sep. 26 at 10:23 AM
$IONS: TRADE CALL activity detected 10 @ 31.30, Strike 40.0, Exp 12/17/2027, Premium $31,300, Sentiment BULLISH
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 26 at 2:30 AM
Enter: $IONS OCT 17 2025 $65 CALLS Buy in Price: $2.00 - $2.20 Take Profit: $3.26 Stop Bleeding: $1.76 ROI Potential: 63% Exit Within: 216 Minutes https://moneygroup.us/alerts
0 · Reply
highnihilism
highnihilism Sep. 24 at 7:11 PM
Russell 2000 (Healthcare) → $HSIC Henry Schein $ICUI ICU Medical $ILMN Illumina $INMD InMode $IONS Ionis Pharmaceuticals
0 · Reply
Quantumup
Quantumup Sep. 24 at 6:24 PM
Leerink⬆️ $QURE's PT to $68/⬆️PoS for AMT-130 to 85%/50% in US/EU from 75%/25%: TD Cowen reit'd $QURE at Buy: RBC Capital⬆️the PT on $QURE to $55 from $24, reiterated at an Outperform and said w/b buyers in2💪🏾given its belief $QURE likely has a Tx for a devastating disease that comes w/ 12X higher risk of committing suicide. $PTCT $WVE $IONS $NBIX Leerink and TD Cowen said in their notes to investors:
0 · Reply
Latest News on IONS
Ionis' brain disorder drug shows promise in clinical trial

Sep 22, 2025, 7:10 AM EDT - 12 days ago

Ionis' brain disorder drug shows promise in clinical trial


Ionis to host investors and analysts for Innovation Day 2025

Sep 8, 2025, 4:00 PM EDT - 26 days ago

Ionis to host investors and analysts for Innovation Day 2025


Is The 35% Rally In IONS Stock Just The Beginning?

Sep 3, 2025, 10:41 AM EDT - 4 weeks ago

Is The 35% Rally In IONS Stock Just The Beginning?


Ionis to present at upcoming investor conferences

Sep 2, 2025, 4:00 PM EDT - 4 weeks ago

Ionis to present at upcoming investor conferences


mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 5 weeks ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX DHR GRAL ILMN MRNA RGEN


US FDA approves Ionis' drug for rare genetic disorder

Aug 21, 2025, 11:58 AM EDT - 6 weeks ago

US FDA approves Ionis' drug for rare genetic disorder


Ionis to hold second quarter 2025 financial results webcast

Jul 16, 2025, 7:05 AM EDT - 2 months ago

Ionis to hold second quarter 2025 financial results webcast


Ionis to host 2025 virtual Annual Meeting of Stockholders

May 6, 2025, 7:05 AM EDT - 5 months ago

Ionis to host 2025 virtual Annual Meeting of Stockholders


Ionis reports first quarter 2025 financial results

Apr 30, 2025, 7:00 AM EDT - 5 months ago

Ionis reports first quarter 2025 financial results


Ionis to host expert panel discussion on sHTG

Apr 3, 2025, 7:05 AM EDT - 6 months ago

Ionis to host expert panel discussion on sHTG


MoneyGroupLLC
MoneyGroupLLC Oct. 4 at 1:10 AM
Enter: $IONS NOV 21 2025 $68 CALLS Buy in Price: $3.95 - $5.60 Take Profit: $7.43 Stop Bleeding: $3.48 ROI Potential: 88% Exit Within: 174 Minutes https://moneygroup.us/alerts
0 · Reply
johnnygogogo
johnnygogogo Oct. 3 at 4:57 PM
$IONS IYAWNIS cc @skeezbag
1 · Reply
SweepCastApp
SweepCastApp Oct. 3 at 3:13 PM
$IONS: Unusual Options Activity Alerted CALL flow observed 300x contracts at Strike price of $70 Exp on 11/21/2025 with Premium of $87K and showing BULLISH Sentiment
0 · Reply
SweepCastApp
SweepCastApp Sep. 30 at 8:12 PM
$IONS: Unusual Options Activity Alerted CALL flow observed 43x contracts at Strike price of $65 Exp on 01/16/2026 with Premium of $27K and showing BEARISH Sentiment
0 · Reply
highnihilism
highnihilism Sep. 30 at 7:34 AM
$LU Lufax: 407 trades, $406K vs $24K avg (17.2x). $383K calls / $23K puts. 99% single-leg. $MTZ Mastec: 224 trades, $462K vs $819K avg (0.56x). $381K calls / $81K puts. 91% single-leg. $LASR Nlight: 82 trades, $384K vs $81K avg (4.75x). $380K calls / $4K puts. 100% single-leg. $IONS Ionis Pharmaceuticals: 123 trades, $438K vs $568K avg (0.77x). $379K calls / $60K puts. 91% single-leg.
0 · Reply
JarvisFlow
JarvisFlow Sep. 26 at 4:59 PM
Goldman Sachs has updated their rating for Ionis Pharmaceuticals ( $IONS ) to Neutral with a price target of 65.
1 · Reply
SweepCastApp
SweepCastApp Sep. 26 at 10:23 AM
$IONS: TRADE CALL activity detected 10 @ 31.30, Strike 40.0, Exp 12/17/2027, Premium $31,300, Sentiment BULLISH
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 26 at 2:30 AM
Enter: $IONS OCT 17 2025 $65 CALLS Buy in Price: $2.00 - $2.20 Take Profit: $3.26 Stop Bleeding: $1.76 ROI Potential: 63% Exit Within: 216 Minutes https://moneygroup.us/alerts
0 · Reply
highnihilism
highnihilism Sep. 24 at 7:11 PM
Russell 2000 (Healthcare) → $HSIC Henry Schein $ICUI ICU Medical $ILMN Illumina $INMD InMode $IONS Ionis Pharmaceuticals
0 · Reply
Quantumup
Quantumup Sep. 24 at 6:24 PM
Leerink⬆️ $QURE's PT to $68/⬆️PoS for AMT-130 to 85%/50% in US/EU from 75%/25%: TD Cowen reit'd $QURE at Buy: RBC Capital⬆️the PT on $QURE to $55 from $24, reiterated at an Outperform and said w/b buyers in2💪🏾given its belief $QURE likely has a Tx for a devastating disease that comes w/ 12X higher risk of committing suicide. $PTCT $WVE $IONS $NBIX Leerink and TD Cowen said in their notes to investors:
0 · Reply
Quantumup
Quantumup Sep. 24 at 6:15 PM
Stifel⬆️the PT on $QURE to $65 from $30, reit'd at Buy and said, we're reiterating our Buy rating on QURE following detailed results from the 3yr AMT-130 data. Bottom line: we believe the data suggest a larger market opportunity (we model >$1B US in 2031) and also a higher probability-of-approval (we model 80%). On the regulatory front, in the context of a broader conversation around "how flexible will the new FDA be?", we think AMT-130 sets up well given (1) the severity of Huntington's-and the fact that most patients are adults, (2) the strength of the AMT-130 efficacy data, (3) QURE's attained alignment with FDA ahead of the 3-year data and (4) QURE's receipt of BTD on the AMT-130 2-year data. And on the market opportunity, there does continue to be the relevant question around capacity, but KOL feedback here has been encouraging, AMT-130 pricing should be high, and we think the HD population should be highly motivated for a potential disease-modifying treatment. $PTCT $WVE $IONS $NBIX
0 · Reply
IN0V8
IN0V8 Sep. 24 at 2:19 PM
$IONS Leerink Partners raises PT to $68.00 from $63.00
0 · Reply
highnihilism
highnihilism Sep. 24 at 12:33 PM
Russell 2000 (Healthcare) → $HSIC Henry Schein $ICUI ICU Medical $ILMN Illumina $INMD InMode $IONS Ionis Pharmaceuticals
0 · Reply
mikesterz7
mikesterz7 Sep. 24 at 12:44 AM
$IONS Guggenheim on Tuesday hiked the price target on the stock to $92 from $90 while keeping a ‘Buy’ rating on the shares.
0 · Reply
anachartanalyst
anachartanalyst Sep. 23 at 7:02 PM
$IONS https://anachart.com/wp-content/uploads/ana_temp/1758654123_soc-img.jpg
0 · Reply
ZacksResearch
ZacksResearch Sep. 23 at 6:22 PM
$IONS soars 76% YTD — what’s driving the momentum? 🚀 Ionis announced positive phase III results for zilganersen in treating Alexander disease, achieving a 33.3% improvement in gait speed stabilization. With plans to seek FDA approval, this marks a significant milestone as the first investigational medicine showing a positive disease-modifying impact in AxD. Discover the full impact here 👉 https://www.zacks.com/stock/news/2755966/ions-rare-neurological-disease-drug-meets-late-stage-study-goal?cid=sm-stocktwits-2-2755966-body-13832&ADID=SYND_STOCKTWITS_TWEET_2_2755966_BODY_13832
0 · Reply
ChessGM
ChessGM Sep. 23 at 6:04 PM
$IONS Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $86
0 · Reply
ZacksResearch
ZacksResearch Sep. 23 at 5:22 PM
$IONS just hit its phase III goal 🚀 Zilganersen succeeded in late-stage trials for Alexander disease, setting up a potential FDA filing in early 2026. See what this milestone means for IONS’ pipeline 👉 https://www.zacks.com/stock/news/2755966/ions-rare-neurological-disease-drug-meets-late-stage-study-goal?cid=sm-stocktwits-2-2755966-teaser-13830&ADID=SYND_STOCKTWITS_TWEET_2_2755966_TEASER_13830
0 · Reply
StocktwitsNews
StocktwitsNews Sep. 23 at 4:03 PM
Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease $IONS $EAOR $PBE https://stocktwits.com/news/equity/markets/ionis-pharma-stock-rises-after-multiple-price-target-hikes/chDLGmZR35v
0 · Reply
ChessGM
ChessGM Sep. 23 at 1:21 PM
$IONS Guggenheim Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $92
0 · Reply
JarvisFlow
JarvisFlow Sep. 23 at 12:31 PM
B of A Securities updates rating for Ionis Pharmaceuticals ( $IONS ) to Buy, target set at 81 → 83.
0 · Reply
ChessGM
ChessGM Sep. 23 at 12:01 PM
$IONS HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $95 Price Target
0 · Reply